Altamira Therapeutics Secures EU MDR Certification for Bentrio Nasal Spray
Altamira Therapeutics Ltd. announced that its associate company, Altamira Medica, has secured EU MDR certification for Bentrio nasal spray, marking a key milestone for its commercialization in EU member states and facilitating regulatory approval in other countries.
Altamira Therapeutics Ltd. announced that its associate company, Altamira Medica, has obtained certification for its Bentrio nasal spray under the European Union’s Medical Device Regulation (MDR). This certification confirms Bentrio’s conformity with the EU’s new, more stringent requirements for medical devices, enabling its commercialization across EU member states and facilitating regulatory approval in other countries. The MDR certification follows significant investment and clinical trials by Medica and marks a key milestone in the international expansion of Bentrio. There is no indication that funding or grant support was provided by organizations other than Altamira or its associate company. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1104155) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
